Korczynski Sherry 4

What Happened

• Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics (AQST), reported a sell-to-cover stock sale and two awards. On 2026-03-10 she disposed of 15,741 shares in open-market transactions for a weighted average price of $4.17, totaling $65,687. On 2026-03-09 she received two acquisitions: 75,000 restricted shares (reported at $0.00) and a 42,500-share derivative grant with a grant-value of $4.29 per share (total ~$182,325).

Key Details

• Transaction dates and prices:
  • 2026-03-09: Award of 75,000 restricted shares (reported $0.00).
  • 2026-03-09: Derivative award of 42,500 shares at $4.29 (total ~$182,325).
  • 2026-03-10: Open-market sale of 15,741 shares at a weighted avg $4.17 (total $65,687). Footnote: sale executed in multiple trades at $4.17–$4.32; $4.17 is the weighted average.
• Shares owned after the transactions: Not disclosed in the filing.
• Notable footnotes:
  • F1/F4: The restricted stock and the options/derivative award vest in three annual installments (25% / 25% / 50%).
  • F2: The 15,741-share sale was a mandatory "sell-to-cover" to satisfy tax withholding on vesting and was not a discretionary trade by the reporting person.
  • F3: Multiple-trade execution; detailed per-trade prices available on request.
• Filing timeliness: Report filed 2026-03-11 for transactions dated 2026-03-09–03-10 (appears filed within the standard Form 4 reporting window).

Context

• The sale appears to be administrative (sell-to-cover for tax withholding) rather than a discretionary exit. The derivative grant and restricted shares are typical compensation awards that vest over time; the derivative grant is not an immediate exercise/sale. As always, awards and mandatory tax sales do not by themselves indicate the insider’s market view.